Table 3.
Association of clinical, pathological and genotypic parameters with radiological response at 4th month of letrozole administration.
| Parameters | Responders (%) | Non-responders (%) | p |
|---|---|---|---|
| Age (years) | |||
| ≤ 78.3 | 19 (54.3) | 29 (48.3) | 0.576 |
| > 78.3 | 16 (45.7) | 31 (51.7) | |
| Histological diagnosis | |||
| IDC | 25 (71.4) | 42 (70.0) | 0.843 |
| ILC | 5 (14.3) | 11 (18.3) | |
| Others | 5 (14.3) | 7 (7.4) | |
| Histological grade | |||
| I | 13 (61.9) | 16 (51.6) | 0.606 |
| II | 6 (28.6) | 13 (41.9) | |
| III | 2 (9.5) | 2 (6.5) | |
| Tumor size (T) | |||
| T2 | 31 (88.6) | 45 (75.0) | 0.111 |
| T3-T4 | 4 (11.4) | 15 (25.0) | |
| Lymph node involvement (N) | |||
| NO | 28 (80.0) | 48 (80.0) | 1.000 |
| N1-2 | 7 (20.0) | 12 (20.0) | |
| Stage | 0.546 | ||
| IIa | 26 (74.3) | 39 (65.5) | |
| IIb | 7 (20.0) | 13 (21.7) | |
| IIIa-IIIb | 2 (5.7) | 8 (13.3) | |
| ER | |||
| ≤ 40% | 3 (8.6) | 10 (16.7) | 0.268 |
| > 40% | 32 (91.4) | 50 (83.3) | |
| PgR | |||
| ≤ 40% | 15 (42.9) | 31 (51.7) | 0.407 |
| > 40% | 20 (57.1) | 29 (48.3) | |
| HR | |||
| ≤ 40% | 2 (5.7) | 8 (13.3) | 0.243 |
| > 40% | 33 (94.3) | 52 (86.7) | |
| HER2 | |||
| 0, + | 21 (60.0) | 42 (70.0) | 0.320 |
| ++, +++ | 14 (40.0) | 18 (30.0) | |
| Ki67 | |||
| Negative | 15 (55.6) | 25 (55.6) | 1.000 |
| Positive | 12 (44.4) | 20 (44.4) | |
| rs10046 | |||
| GG | 6 (17.1) | 9 (15.0) | 0.782 |
| AG/AA | 29 (82.9) | 15 (85.0) | |
| rs4646 | |||
| CC | 26 (74.3) | 31 (51.7) | 0.030 |
| AC/AA | 9 (25.7) | 29 (48.3) |